Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Polyunsaturated Fatty Acid Intake during Complementary Feeding and Neurodevelopmental Outcome in Very Low Birth Weight Infants

  • Melanie Gsöllpointner
  • , Margarita Thanhaeuser
  • , Fabian Eibensteiner
  • , Robin Ristl
  • , Bernd Jilma
  • , Renate Fuiko
  • , Sophia Brandstetter
  • , Angelika Berger
  • , Nadja Haiden

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

Abstract

Polyunsaturated fatty acids (PUFAs) are vital for brain development, yet limited knowledge exists regarding PUFA intake during complementary feeding (CF) and its impact on neurodevelopmental outcomes in very low birth weight (VLBW) infants. This secondary analysis of a randomized intervention trial, aimed to investigate the association between dietary intake of total PUFAs, arachidonic acid (AA), and docosahexaenoic acid (DHA) during CF and neurodevelopmental outcomes at 12 and 24 months of corrected age (CA). Dietary intakes were assessed using monthly 3 day dietary protocols from 3 to 12 months CA. Neurodevelopmental outcome was evaluated using the Bayley Scales of Infant Development-III. Among the 177 randomized patients, PUFA intake and neurodevelopmental outcomes were evaluated in 140 (79%) infants. Higher total PUFA and DHA intakes significantly correlated with improved cognitive and motor function at 12 months CA, while increased AA intake notably enhanced motor scores at 12 months CA. However, median dietary intakes of AA and DHA (AA: 53.50–84.25 mg/d; DHA: 51.47–76.23 mg/d) fell short of recommended levels (AA: 140 mg/d; DHA: 100 mg/d) at any of the investigated timepoints. These findings emphasize the need to enhance total PUFA, DHA and AA intakes during CF, ensuring adherence to guidelines and unlocking the potential to improve neurodevelopmental outcomes in VLBW infants.
OriginalspracheEnglisch
Aufsatznummer3141
Seitenumfang14
FachzeitschriftNutrients
Volume15
Ausgabenummer14
DOIs
PublikationsstatusVeröffentlicht - 14 Juli 2023

Wissenschaftszweige

  • 303 Gesundheitswissenschaften
  • 304 Medizinische Biotechnologie
  • 305 Andere Humanmedizin, Gesundheitswissenschaften
  • 301 Medizinisch-theoretische Wissenschaften, Pharmazie
  • 302 Klinische Medizin

JKU-Schwerpunkte

  • Digital Transformation
  • Sustainable Development: Responsible Technologies and Management

Dieses zitieren